BrightPath's Update on the Pre-clinical Data of BP1200 and BP1209

BrightPath Biotherapeutics (TSE Mothers 4954) announces that at the European Society for Medical Oncology Congress of 2021<https://www.esmo.org/meetings/esmo-congress-2021> (ESMO 2021) on September 16-21, pre-clinical studies on BP1200, anti-CD73 monoclonal antibody, and BP1209, a new personalized neoantigen vaccine platform, will be published in the form of posters. Summary of the abstracts and electronic posters will be posted on the website of BrightPath at https://www.brightpathbio.com/english/index.html after ESMO 2021 is held.

BP1200
Research title: A novel therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy.
Abstract number: 987P

BP1209
Research title: A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies to improve cancer immunity.
Abstract number: 1005P